Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYB | P10242 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4535802 | 0.84 | ALDH1A1 (0.55) | MYBALDH1A1NPC1PKMHPGD | |
| SCHEMBL5045119 | 0.82 | MEN1 (0.56) | MYBALDH1A1NPC1PKMHPGD | |
| SCHEMBL15363767 | 0.80 | ALDH1A1 (0.67) | MYBALDH1A1NPC1PKMHPGD | |
| SCHEMBL5045714 | 0.80 | MYB (1.00) | MYBLMNAMAPTMEN1KMT2A | |
| SCHEMBL4535837 | 0.74 | TUBB4A (0.69) | MYBALDH1A1NPC1PKMHPGD | |
| SCHEMBL4537382 | 0.71 | ESR1 (0.52) | ALDH1A1PKMMAPTMEN1KMT2A | |
| SCHEMBL5959230 | 0.70 | NPC1 (0.81) | ALDH1A1NPC1HPGDLMNAMAPT | |
| SCHEMBL4335448 | 0.69 | MEN1 (0.76) | ALDH1A1NPC1PKMHPGDLMNA | |
| SCHEMBL4325650 | 0.69 | MEN1 (0.65) | MYBALDH1A1NPC1PKMHPGD | |
| SCHEMBL5959438 | 0.68 | NPC1 (1.00) | ALDH1A1NPC1HPGDLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638025-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2020-02-05 | — | — | EP | disclosed |
| EP-2638025-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2020-02-05 | — | — | EP | disclosed |
| US-20180334442-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | Ruprecht-Karls-Universität Heidelberg (DE) | 2018-11-22 | — | — | US | disclosed |
| US-10065939-B2 | Chromene derivatives and their analogs as Wnt pathway antagonists | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2018-09-04 | — | — | US | disclosed |
| EP-2638026-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2018-07-11 | — | — | EP | disclosed |
| EP-2638026-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2018-07-11 | — | — | EP | disclosed |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-12-08 | — | — | US | disclosed |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-12-08 | — | — | US | disclosed |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-12-08 | — | — | US | disclosed |
| US-9371333-B2 | Chromene derivatives and their analoga as Wnt pathway antagonists | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-06-21 | — | — | US | disclosed |
| US-20130303550-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-07 | — | — | US | disclosed |
| EP-2638026-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | Deutsches Krebsforschungszentrum (DKFZ) (DE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2638025-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | Deutsches Krebsforschungszentrum (DKFZ) (DE) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062905-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062905-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062901-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062901-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303550-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | MYB 142/4885ALDH1A1 3782/4885NPC1 1885/4885 |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | MYB 152/4885ALDH1A1 4092/4885NPC1 1570/4885 |
| US-10065939-B2 | Chromene derivatives and their analogs as Wnt pathway antagonists | WNT3, WNT1, WNT3A | MYB 152/4885ALDH1A1 4092/4885NPC1 1570/4885 |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | MYB 172/4885ALDH1A1 3312/4885NPC1 4529/4885 |
| US-20180334442-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | MYB 152/4885ALDH1A1 4092/4885NPC1 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.